Teva Pharmaceuticals

Teva Pharmaceuticals Presents Real-World Data for Austedo Tablets

Psych Congress Elevate 2023 Annual Meeting

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceuticals, presented 12 presentations across its neuroscience portfolio at the Psych Congress Elevate 2023 Annual Meeting. One of the presentations included real-world data for Austedo (Deutetrabenazine) Tablets with a 4-week patient titration kit. Austedo Tablets are used to treat chorea associated with Huntington's disease and tardive dyskinesia. The real-world data presented at the meeting showed that the 4-week patient titration kit was effective in managing the side effects associated with the medication. Teva Pharmaceuticals is committed to developing innovative treatments for patients with neurological conditions. The real-world data presented at the Psych Congress Elevate 2023 Annual Meeting demonstrates Teva's dedication to improving patient outcomes through research and development. In summary: Teva Pharmaceuticals presented real-world data for Austedo Tablets with a 4-week patient titration kit at the Psych Congress Elevate 2023 Annual Meeting. The data showed that the kit was effective in managing side effects associated with the medication. Teva Pharmaceuticals is dedicated to developing innovative treatments for patients with neurological conditions. Source: NDA News